Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Friday, April 8, 2011

Laquinimod, Alemtuzumab, CCSVI, and much more, to be discussed at the AAN meeting in Hawaii, April 9th thru 16th



Showing just a few of what will be discussed: 
 
Teva to present Laquinimod data at Hawaii conference
Globes Online Thu, 07 Apr 2011 09:21 AM PDT
The Phase III trial of the oral multiple sclerosis drug showed a statistically significant reduction in annualized relapse rate and in the disability progression.

Press Release
PharmiWeb Thu, 07 Apr 2011 08:04 AM PDT
Genzyme , a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis (MS) at the American Academy of Neurology's (AAN) 63rd Annual Meeting in Hawaii, April 9 - 16, 2011. Included among the additional Phase 2 trial safety and efficacy data at AAN ...
Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy Of Neurology
Business Wire Thu, 07 Apr 2011 06:21 AM PDT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis (MS) at the American Academy of Neurology's (AAN) 63rd Annual Meeting in Hawaii, April 9 - 16, 2011. Included among the additional Phase 2 trial ...
 
 
Press Release
PharmiWeb Fri, 08 Apr 2011
EMD Serono Inc. Posted on:08 Apr 11 EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple sclerosis (MS) portfolio will be presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN) taking place from April 9 to 16, in Honolulu, Hawaii.


****************************************************************
Remain CURRENT with Multiple Sclerosis information 
 when registered at the  MS Views and News  website
.
***************************************************************************************
Help to Educate:  Please donate   - all contributions are tax deductible - 
.
"Providing You with 'MS Views and News'is what we do"
***************************************************************************************
.
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
.
 ****************************************************************

Tysabri Label Modified to Include More Brain Infection Data


April 8, 2011
Tysabri, the multiple sclerosis drug marketed by Biogen Idec Inc. and Elan Corp is having its label updated to include new data about the incidence of progressive multifocal leukoencephalopathy, or PML, a rare brain infection. According to a report from The Wall Street Journal, the U.S. Food & Drug Administration (FDA) will be posting a “Drug Safety Communication” on the label changes in the coming days.
The new Tysabri label information includes a table that details the incidence of PML. It also includes information on a newly identified PML risk factor of patients taking certain immune-system suppressing medication prior to taking Tysabri, the Journal said.
PML attacks the brain and central nervous system and is usually fatal. Symptoms include vision problems, loss of coordination, and memory loss. Patients who survive the disease are often permanently disabled.
The data in the newly-added table – current as of January – shows the risk of getting the infection is 0.3 patients per 1,000 when using the drug for less than two years, the Journal said. That rate rises when using the drug for two to three years, to 1.5 cases, but drops to 0.9 cases for the period of three to four years.
****************************************************************
Remain CURRENT with Multiple Sclerosis information 
 when registered at the  MS Views and News  website
.
***************************************************************************************
Help to Educate:  Please donate   - all contributions are tax deductible - 
.
"Providing You with 'MS Views and News'is what we do"
***************************************************************************************
.
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
.
 ****************************************************************

CCSVI update: Saskatchewan and Manitoba partner on liberation treatment



April 7, 2011

Saskatchewan Premier Brad Wall and Manitoba Premier Greg Selinger have announced that the provinces are working together to advance clinical trial research on the multiple sclerosis (MS) liberation treatment.

The Province of Manitoba will invest $5 million in MS research and follow the Saskatchewan Health Research Foundation (SHRF) protocols in a complementary research process in Manitoba.

Saskatchewan became the first province to initiate clinical trials for the MS liberation procedure when it announced a $5 million investment and launched a call for proposals in December 2010.

The SHRF is managing the publicly funded health research process, has developed a competitive call for clinical trials and appointed an expert advisory panel. A research proposal that will lead to clinical trials will be selected soon.

Manitoba has matched Saskatchewan's $5 million commitment towards liberation treatment research.

The Manitoba Health Research Council (MHRC) will issue a call for proposals following consultations with the SHRF to ensure proposal criteria and review processes are complementary.

"MS patients and their families deserve to know as quickly as possible whether this experimental procedure is the breakthrough so many of us hope it is," Selinger said. "This partnership will help us get the answers we urgently need while providing Manitobans a chance to participate early in the clinical trial process."

"Saskatchewan is committed to advancing the science in MS diagnosis and treatment," Wall said. "We are pleased that Manitoba is proceeding with its own clinical trials, furthering efforts to get answers for people who suffer from this devastating disease."

The liberation procedure is a potentially ground-breaking discovery for the treatment of MS. However, it is not yet proven as a scientifically valid therapy. The funding announced will help produce more extensive data and ultimately, may determine the procedure's validity as a treatment for MS.



Continue reading
====================
****************************************************************
Remain CURRENT with Multiple Sclerosis information 
 when registered at the  MS Views and News  website
.
***************************************************************************************
Help to Educate:  Please donate   - all contributions are tax deductible - 
.
"Providing You with 'MS Views and News'is what we do"
***************************************************************************************
.
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
.
 ****************************************************************

More evidence pregnancy is safe with MS


NEW YORK | Thu Apr 7, 2011 4:23pm EDT
(Reuters Health) - A new research review strengthens the evidence that women with multiple sclerosis are about as likely as other women to have a healthy pregnancy -- without putting their own health at risk.
The findings, reported in the obstetrics journal BJOG, support the advice generally given to women with multiple sclerosis: If the condition is under control, you can safely become pregnant.
"A woman with multiple sclerosis can consider pregnancy just the same way all other women consider it," Dr. Yara D. Fragoso, a neurologist at the Universidade Metropolitana de Santos in Brazil, and the senior researcher on the new study, told Reuters Health.
Multiple sclerosis, or MS, is a nerve disorder thought to arise when a person's immune system mistakenly attacks that person's own nerve fibers. MS leads to symptoms like muscle weakness, numbness, vision problems and difficulty with coordination and balance.
Years ago, women with MS were advised to avoid pregnancy, partly out of concern that it could make their disease worse.
But studies in recent decades have shown that the opposite is true; many women see their symptoms improve or even disappear during pregnancy -- possibly because immune system activity naturally declines and levels of anti-inflammatory hormones called corticosteroids naturally rise during pregnancy.
****************************************************************
Remain CURRENT with Multiple Sclerosis information 
 when registered at the  MS Views and News  website
.
***************************************************************************************
Help to Educate:  Please donate   - all contributions are tax deductible - 
.
"Providing You with 'MS Views and News'is what we do"
***************************************************************************************
.
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
.
 ****************************************************************